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INTRODUCTION 
Bleeding after cardiac surgery is a major complication that affects 18% 
of patients undergoing cardiac surgery. Subsequent transfusion of blood and 
blood products puts the patient at risk for transfusion reactions and transfusion 
acquired infections. The mechanism of bleeding is subclinical induction of 
fibrinolysis and platelet receptor damage. These changes are induced by 
activation of factor XII caused by contact with CPB circuit, initiating a 
systemic inflammatory response involving coagulation cascade, fibrinolysis 
and compliment activation. Also, hypothermia during CPB causes reversible 
platelet membrane dysfunction, inhibition of coagulation factors and  
disordered fibrinolysis. 
 
The antifibrinolytic tranexamic acid and platelet stabilising ethamsylate 
when used in combination helps reduce post operative bleeding. This study 
aims at comparing the efficacy of oral versus intravenous combination of the 
above said drugs in controlling blood loss. 
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2 
 
 
AIMS & OBJECTIVES 
To know the effect of tranexamic acid in reducing intraoperative and 
postoperative blood loss in patients undergoing cardiac valve replacement 
surgeries. 
The secondary purpose of the study is 
1. To know the requirement of transfusion intraoperatively and post 
operatively.  
2. To study the effect of drug on haematocrit change after surgery. 
3. To compare the cost effectiveness of the 2 groups. 
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PHARMACOLOGY OF TRANEXAMIC ACID  
It is an antifibrinolytic agent with the chemical name  
Trans-4-(aminomethyl) cyclohexane carboxylic acid. 
pH = 6.5 – 8.0 
EMPERICAL FORMULA =  C8H15NO2 
MOLECULAR WEIGHT = 157.2 
STRUCTURAL FORMULA 
 
 
 
 
 
MECHANISM OF ACTION: 
o It is a synthetic lysine derivative that inhibits fibrinolysis by blocking the 
lysine binding sites on plasminogen. 
o It is a competitive inhibitor of plasminogen activation and at higher 
concentrations, a non- competitive inhibitor of plasmin. This action is 
similar to that of epsilon-aminocaproic acid but tranexamic acid is 10 
times more potent. 
4 
 
o In concentrations of upto 10mg/ml it has no effect on platelet counts, 
clotting time or clotting factors in whole blood. But in concentrations of 
10mg/ml to 1g/ml it prolongs thrombin time. 
PHARMACOKINETIC AND PHARMACODYNAMICS: 
Plasma protein binding is almost equal to 3% and mainly binds to 
plasminogen mainly and does not bind to albumin. The half life of intravenous 
dose of 1g is 2hours. The antifibrinolytic concentration remains in different 
tissues for 17hours and in serum for upto 7-8hours. 
Volume of distribution is about 9 to 12 L. Elimination is mainly via 
glomerular filtration. Renal clearance is 110 – 116ml/min and more than 95% 
of the drug is excreted in urine unchanged. Following administration of drug 
intravenously at the dose of 10mg/kg body weight, excretion is almost 90% at 
24hours. 
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Tranexamic acid can cross the placenta and it is secreted into the breast 
milk at a concentration of 1/100th of plasma concentration.  
INDICATIONS: 
I. MEDICAL: 
 Hereditary angioneurotic edema[1] 
 Upper gastro intestinal bleeding.[2,3] 
 Reversal of drug induced bleeding (eg., TPA, Dabigatran, 
Rivaroxaban, Fondaparinux induced bleeding). 
 Menorrhagia.[4,5] 
II. ELECTIVE SURGERY 
 Oral surgeries[6,7] 
 Obstetrics and gynaecology surgeries for treatment of 
menorrhagia and post partumhaemorrhage[8,9,10] 
 Cardiac surgeries: it decreases the blood loss without 
increasing the risk of thromboembolism.[11] 
 Orthopaedic surgery: In joint arthroplasty and spine surgeries, 
there is evidence oral and intra-articular administration may 
be beneficial.[12,13] 
 Liver: decreases transfusion in liver surgeries – resection  and 
transplant surgeries. 
 ENT/ Maxillo facial surgeries: decreases the total blood loss 
in tonsillectomy patients. It is used to treat epistaxis. 
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 Neuro surgeries: decreases the rate of re-bleeding[14,15] 
 Urology: decreases the blood loss after TURP and serious 
hematuria.[16] 
 It is also used to treat major hemoptysis. 
III. TRAUMA: 
Fibrinolysis is a recognized early feature of severe trauma which 
requires transfusions in trauma ward. Tranexamic acid is a reliable 
safe and most effective treatment.[17,18,19] 
CONTRAINDICATIONS: 
 Acquired defective colour vision. 
 Subarachnoid haemorrhage. 
 Patients with active intravascular clotting. 
 Hypersensitivity to tranexamic acid. 
PRECAUTIONS: 
 Dose reduction is to be considered in patients with renal insufficiency. 
 This drug may cause dizziness. 
 In patients with history of thromboembolism there is increased risk of 
venous and arterial thrombosis 
 Retinal artery and vein obstruction have also been reported. 
DRUG INTERACTIONS: 
 There is no data regarding interactions with other drugs. 
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PHARMACOLOGY OF ETHAMSYLATE 
It is a hemostatic, non-thrombogenic agent discovered by Esteve et al in 
1959. 
CHEMICAL FORMULA: 2,5dihydroxy-benzene-sulphonate diethyl 
ammonium salt. 
STRUCTURAL FORMULA: 
 
 
 
 
 
 
MECHANISM OF ACTION: 
 Ethamsylate is a synthetic hemostatic drug which acts on the first step of 
hemostasis by improving the platelet adhesiveness and restoring 
capillary resistance. 
 Sack & Cerutti[20] showed that “ethamsylate decreases electrophoretic 
mobility of platelets and suggested that a reduction in negative 
membrane charge allowed formation of bridges between adjacent 
platelets in stirred systems.” 
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 It promotes p-selectin dependent platelet adhesion. 
 It is found to inhibit prostaglandin biosynthesis independent of 
cyclooxygenase inhibition. 
 It has no vasoconstrictor action, it does not influence fibrinolysis or 
modify the plasma coagulation factors.  
PHARMACOKINETICS: 
ORAL ADMINISTRATION: 
 Oral dose of 500mg leads to plasma concentration of 60 micrograms/L 
after 4hours with 95% bound to plasma proteins. Free plasma 
concentration of drug is 3micrograms/L. 
 Plasma half life is 3.7hours. 
 Elimination half life is 8hours and excreted unchanged in urine. 
 It crosses placenta and is not known to be secreted in breast milk. 
INTRAVENOUS ADMINISTRATION: 
 500mg of intravenous ethamsylate leads to maximum plasma levels of 
50micrograms/ml reached within 10min of administration. 
 Plasma half life is 1.9hours 
 Elimination half life is 2hours and 85% is excreted in first 24hours. 
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INDICATIONS: 
 Menorrhagia[21] 
 Periventricular hemorrhage in low birth weight babies[22,23] 
 Surgical and post surgical bleeding control[24,25]: 
o Tonsillectomy 
o Cataract surgeries 
o Prostatectomy[26] 
o Vaginal surgeries 
o Total hip replacements[27] 
o Aspirin induced gastric mucosal bleeding. 
SIDE EFFECTS: 
Most common side effects include nausea, gastritis, headache and skin 
rashes. Most of these disappear spontaneously. Earlier DVT was thought to 
occur in patients treated with ethamsylate but in a study conducted by Symes et 
al, it was concluded that “there is no clinical evidence of DVT in ethamsylate 
or placebo group.” 
CONTRAINDICATIONS: 
 Acute porphyria 
 Safer to avoid in first trimester of pregnancy. 
DRUG INTERACTIONS: 
 There is no data regarding interactions with other drugs. 
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STORAGE: 
 Protect the ampuoles from light. 
 Discard if the solution is coloured.
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REVIEW OF LITERATURE 
 De Reynier (1965) in his study administered 250mg ethamsylate 
intramuscularly and 250mg intravenously 1 hour before surgery, followed 
by 250mg intravenous just before induction and found a mean reduction of 
blood loss of 27 % of adults.  
 Papatheodossiou (1973) investigated the effect of ethamsylate on peri and 
postoperative blood losses in 200 cases of tonsillectomy (ethamsylate was 
given before and after surgery) the results of which showed a mean blood 
loss of 4.86 ml in the ethamsylate group, against 27.5 ml in the placebo 
group. Two cases under placebo had postoperative hemorrhages 
(Papatheodossiou, 1973).  
 Arora and Manford (1979) found that secondary hemorrhage was 
significantly less in children treated with ethamsylate. It is difficult to 
compare the results of these trials, as they all differ in some respects. For 
instance, operative blood losses were small in the placebo group of Arora 
and Manford (1979) compared with those reported by other authors 
carrying out dissection tonsillectomy and curettage of the adenoids under 
general anaesthesia in children. Another factor is the considerable inter-
individual variation in blood loss within the groups, eg. different surgeons 
carrying out operations. 
 In 1975, Symes et al.[26] performed a double-blinded trial in 76 patients (in 
the ethamsylate group, 1 g ethamsylate was intravenously given in the 
anaesthetic room, followed by 250 mg intramuscularly at 4 hourly intervals 
12 
 
until micro hematuria was ceased), where: median loss of blood at operation 
was 17 ml in those given ethamsylate compared with 72 ml in the placebo 
group (p < 0.001). median postoperative blood loss was 38 ml in the 
ethamsylate group, and 103 ml in the placebo group (p < 0.05). 
 Four double-blind trials were designed to investigate the therapeutical 
efficacy of ethamsylate in dysfunctional uterine bleeding, with positive 
results in all four studies (Jaffe and Wickham, 1973; Harrison and 
Campbell, 1976; Kovacs and Annus, 1978; Levrier et al., 2003). Of these, 
Harrison and Campbell (1976) found that ethamsylate reduced mean 
menstrual blood loss more in patients with primary menorrhagia (-50%) 
than in women using intrauterine devices (-19%; ethamsylate was given in 
2x250 mg tablets, four times a day, starting 5 days before the anticipated 
onset of menstruation and continuing for 10 days). 
 Keith[27] has demonstrated that intravenous ethamsylate administered prior 
to the induction of anaesthesia does not reduce the average volume of blood 
lost during and after total hip replacement under lumbar epidural 
anaesthesia. He has suggested that the effect of ethamsylate may decrease 
as the degree of tissue trauma and haemorrhage increases. 
 The Blood Conservation Using Antifibrinolytics in a Randomized Trial – 
BART Trial was published by Fergusson et al. compared the use of 
aprotinin, TXA and E-ACA in high-risk cardiac surgery patients and found 
that the 30-day mortality rate was 6% for the aprotinin group vs 3.9% for 
TXA (RR 1.55) and 4.0% for E-ACA (RR 1.52). BART protocol used 
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tranexamic acid regimen of 30 mg/kg loading dose followed by 16mg/kg/hr 
infusion during surgery with an added 2 mg/kg in the circuit (high dose 
range). 
 Horrowet al.[28] undertook studies in cardiac surgeries and found that a 
prophylactic loading dose of 10mg/kg with infusion at 1mg/kg/hr was 
optimal, when compared to six incremental loading doses from 2.5 to 40 
mg/kg followed by 0.25 mg to 4 mg/kg/ h infusion. A recent RCT pitted the 
Horrow regimen against the higher BART regimen in cardiac surgery 
patients, and it was found that although a high dose of Tranexamic acid 
does not reduce the incidence of blood product transfusion up to day7 (63% 
low dose vs 60% high dose), it is more effective than a low dose of TXA in 
decreasing transfusion (2.5 vs 4.1 U), blood loss (590 vs 820 mL), and 
repeat surgery (2.5% vs 6%). 
 A large retrospective analysis by Poeran et al. studied the perioperative use 
of TXA in knee or hip arthroplasty (n = 872416). Patients who received 
TXA had lower rates of blood transfusion (7.7 vs 20.1%), fewer 
thromboembolic events (0.6 vs 0.8%), and reduced incidence of acute renal 
failure (1.6 vs 1.8%) as well as combined complications (1.9 vs 2.6%). 
With an increasing dose of TXA (none, < 1 g, ~ 2 g and > 3 g), there were 
decreasing odds (OR 0.31 to 0.38) of blood transfusion, and no significant 
increased risk of complications. 
 CRASH -2 Trial[17,18] was a large randomised double blinded placebo- 
controlled multicentre clinical trial that included 20211 adult trauma 
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patients in 274 hospitals in 40 countries with or at risk of severe bleeding. 
They were randomised into 2 groups – one with tranexamic acid and the 
other with placebo. It reported that TXA use resulted in a statistically 
significant reduction in the relative risk (RR) of all-cause mortality of 9% 
(14.5% vs. 16.0%; RR, 0.91; confidence interval [CI], 0.85–0.97; p _ 
0.0035). It also reported a reduction in RR of death as a result of bleeding 
of 15% (4.9% vs. 5.7%; RR, 0.85; CI, 0.76–0.96; p _ 0.0077). Similarly, 
they reported an RR reduction in death as a result of bleeding on the day of 
randomization of 20% (2.8% vs. 3.5%; RR, 0.80; CI, 0.68–0.93; p _ 
0.0036). It was in this group of most severely injured patients that use of 
TXA was associated with the greatest reduction in risk of death. The benefit 
of TXA was greater in patients treated within 3 hours of injury and in 
patients with a presenting systolic blood pressure of around 75 mm Hg 
compared with those with normal systolic blood pressures.  
 A nested RCT within CRASH-2 by Perel et al. reviewed the rate of 
Intracranial hemorrhage growth in 270 patients, and they found no 
moderate benefits (total hemorrhage growth and/or new ischemic lesions) 
nor harmful effects with certainty in traumatic brain injury. 
 Caglaret al.[10] were the first to study the effect of TA in myomectomy in a 
RCT, 50 women in each group. TA reduced with statistical significance the 
postoperative and total blood loss as well as duration of surgery compared 
to the control group but the blood transfusion requirements were similar in 
both groups. 
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MATERIALS AND METHODS 
 The study was conducted at Institute Of Anesthesiology And Critical 
Care, Madras Medical College between October 2017 to March 2018, after 
obtaining institutional ethical committee approval. The aim of this study is to 
know the effect of tranexamic acid in reducing intraoperative and postoperative 
blood loss in patients undergoing cardiac valve replacement surgeries. 
STUDY DESIGN:  
Prospective, randomized, case control study. 
 
INCLUSION CRITERIA: 
 Elective surgery  
 Who have given valid informed consent. 
 Aged 18 to 60years 
 
EXCLUSION CRITERIA: 
 Known allergy to either of the drugs 
 History/ evidence of coagulopathy and bleeding disorder  
 Renal dysfunction (Creatinine > 1.5) 
 Thromboembolic event 1yr prior to surgery 
 Hemoglobin <8gm/dl 
 Not satisfying inclusion criteria 
 Lack of written informed consent 
 Emergency surgery.  
16 
 
MATERIALS: 
 18G venflon needle 
 5ml syringe 
 Tranexamic acid and ethamsylate oral and IV preparations 
 Normal saline 
 Other drugs used in routine general anesthesia and cardiac surgeries.  
 
MONITORS: 
 Heart rate 
 NIBP 
 IBP 
 Pulseoximetry  
 Capnography 
 CVP 
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STUDY OUTCOME MEASURES: 
 PRIMARY OUTCOME MEASURES:  
o Volume of Blood loss intraoperatively and postoperatively up to 
first 24hours. 
 SECONDARY OUTCOME MEASURES:  
o Bleeding time, clotting time, platelet count. 
o Post-operative hemoglobin and hematocrit values 
o Number of packed cells transfused intraoperatively and 
postoperatively. 
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METHODOLOGY 
 All the patients were assessed in our assessment clinic and informed 
consent was obtained after explaining the study. Patients who didn’t meet the 
inclusion and exclusion criterias were not included in the study. 
 Patients were randomly allocated according to computer generated 
tables into two groups. Group O (oral = 30 patients) received Tab. Ethamsylate 
250 mg + Tab. Tranexamic acid 500 mg which was started 24 hours prior to 
surgery given at 8 hourly interval; Last dose given 2 hours prior to surgery with 
sips of water. Group I (Intravenous = 30 patients) received I.V.  Ethamsylate 
250 mg + I.V.  Tranexamic acid 500 mg given at 2 hourly intervals with the 
first dose given at the time of induction. 
 
 On arrival of patient in operation room, monitors were connected and 
two peripheral lines were secured. All patients received Inj.Glycopyrrolate 
0.2mg iv + inj. Midazolam 1-2mg iv + inj. Fentanyl 40mcg iv. Central line 
(right internal jugular vein predominantly) and arterial line (left radial artery 
predominantly) were cannulated and secured. Patients were induced with 
intravenous inj. Fentanyl at 5-7mcg/kg + inj.Thiopentone 1-2mcg/kg (sleeping 
dose of Thiopentone) and paralysed with inj.Vecuronium 0.08-0.12mg/kg and 
were intubated with appropriate size tubes and secured. 
 
Anesthesia were maintained with nitrous oxide: oxygen = 2:2 and 
isoflurane or sevoflurane. Intraoperative blood loss in the form of soaked pads 
and gauze were noted and transfusions given were noted. Serial ABG and ACT 
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monitoring were done. Post operatively all patients were shifted to Intensive 
care unit for elective post operative and  ventilation.  
 
 Postoperatively patients were monitored for blood loss(drain), 
hemoglobin, Bleeding time, clotting time upto 24 hours.  
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STATISTICAL ANALYSIS 
The raw data were initially entered to Microsoft Excel 2010 and these 
spreadsheets were used for analysis in SPSS. Statistical analysis was done 
using SPSS version 20.0.  
 Descriptive statistics were calculated as frequency, percentage, mean 
and standard deviation. Descriptive data were represented using various 
tables and graphs 
 For all the statistical tests of significance, p value of <0.05 was 
considered to reject the null hypothesis.  
 After the normality tests showed normal distribution of continuous 
variables, independent samples student ’t’ test was done to test the 
difference in means of continuous variables at various time intervals 
between the IV group and oral group. 
 Paired ’t’ test was done to test the difference in means of continuous 
variables before and after surgery between the IV group and oral group. 
For categorical nominal variables, Chi-square test was done to test the 
difference in proportion of the variables between the IV group and oral group. 
For non-normally distributed continuous variable, the difference 
between medians was done using Mann-Whitney test. 
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ANCOVA test was applied to test the difference in mean levels of 
hemodynamic parameters (continuous dependent variable) in the post-operative 
period between the IV group and oral group (categorical independent variable) 
with baseline levels as covariate. 
Repeated measures ANOVA was applied to test the difference in mean 
activated clotting time at various time intervals between the IV group and oral 
group (categorical independent variable used as between subjects factor) as 
ACT levels (continuous dependent variable) was measured thrice. 
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SAMPLE SIZE CALCULATION 
According to a study done by Rajkumar et al, average blood loss was found 
to be 700ml in tranexamic acid group. 
STUDY: Tranexamic acid in controlling the postoperative bleeding in open 
heart surgical patients – a study report. 
Authored By: Satyavolu Rajkumar et al. 
Published In: Indian journal thoracic and cardiovascular surgery, 2005; 
21: 207-211 
Assuming the blood loss in Group A to be 700 ml and to study a 
difference of 75 ml reduction in blood loss in Group B with a S.D of 100 ml in 
both groups, and using an alpha of 0.05 and equal allocation of subjects in each 
groups, to achieve 80% power, the minimum required sample size is 28 in each 
treatment arm..Total sample size required: 56 
23 
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METHODOLOGY 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethics Committee Approval 
Patient satisfying inclusion criteria 
Informed Consent Obtained 
Randomization of Patients by Computer generated table 
Group I (Intravenous) Group O (Oral) 
Hematocrit, BT, CT, Platelets, Activated 
Clotting Time 1 day prior to surgery 
HCT, Bleeding Time, Clotting Time, 
Platelet count, ACT just before surgery 
Tab. Ethamsylate 250 mg 
+ 
Tab. Tranexamic acid 500 mg 
Started 24 hrs prior to Surgery 8 hourly 
interval; Last dose 2 hrs prior to Surgery 
with sips of water 
I.V.  Ethamsylate 250 mg 
+ 
I.V.  Tranexamic acid 500 mg 
Before incision; Pre by-pass; 
During by-pass; Post by-pass at 2 
hourly intervals 
Standard protocol based premedication, 
induction of GA and intubation followed. 
ACT done:  
prior to by-pass  / during by-pass /  
post by-pass 
Intra op blood loss measurement and transfusion requirement 
END of SURGERY 
Post op blood loss assessment, HCT, BT, CT, Platelet Count  
(24 hrs after Surgery) 
Data Compilation & Statistical Analysis 
CONCLUSION 
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OBSERVATION & RESULTS 
Table 1: Age distribution of the study groups (n=60) 
Age group 
I.V Group 
n (%) 
Oral Group 
n (%) 
Total 
n (%) 
20 - 30 years 4 (13.3) 6 (20) 10 (16.7) 
31 - 40 years 11 (36.7) 9 (30) 20 (33.3) 
41 - 50 years 5 (16.7) 6 (20) 11 (18.3) 
51 - 60 years 10 (33.3) 9 (30) 19 (31.7) 
Total 30 (100) 30 (100) 60 (100) 
 
Mean (± S.D) Age of IV group:  42.57 ± 10.77 
Mean (± S.D) Age of Oral group:  42.03 ± 11.458 
Chi-square value: 0.744            p value: 0.863   
Comments:  
 Age distribution of subjects in both the groups were comparable and the 
minimal difference observed was not statistically significant. 
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Fig 1: Age distribution of the study groups (n=60) 
 
  
4
11
5
10
6
9
6
9
0
2
4
6
8
10
12
20 - 30
years
31 to 40
years
41 to 50
years
51 to 60
years
IV Oral
27 
 
 
 
Table 2: Gender distribution of the study groups (n=60) 
Group 
Female 
n (%) 
Male 
n (%) 
Total 
n (%) 
I.V Group 21 (70) 9 (30) 30 (50) 
Oral Group 9 (30) 21 (70) 30 (50) 
Total 30 (100) 30 (100) 60 (100) 
Chi-square value: 9.600            p value: 0.002   
Comments:  
 The difference in gender distribution of subjects in the groups was 
statistically significant with I.V group having more females than oral group and 
vice-versa. 
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Fig 2: Gender distribution of the study groups (n=60) 
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Table 3: Distribution of the subjects according to diagnosis (n=60) 
 
Diagnosis 
I.V Group 
n (%) 
Oral Group 
n (%) 
Total 
n (%) 
Single valve disease 19 (63.3) 22 (73.3) 41 (68.3) 
Double valve disease 11 (36.7) 7 (23.3) 18 (30) 
Triple valve disease 0 1 (3.3) 1 (1.7) 
Total 30 (100) 30 (100) 60 (100) 
 
Chi-square value: 2.108             p value:0.348 
Comments:  
 The difference in distribution of diagnosis based on number of valves 
involved between the groups was not statistically significant. 
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Fig 3: Distribution of the subjects according to diagnosis (n=60) 
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Table 4: Distribution of the subjects according to surgical procedure 
(n=60) 
 
Procedure 
I.V Group 
n (%) 
Oral Group 
n (%) 
Total 
n (%) 
Aortic valve replacement (AVR) 7 (23.3) 10 (33.3) 17 (28.3) 
Mitral valve replacement (MVR) 16 (53.3) 14 (46.7) 30 (50) 
Double valve replacement (DVR) 2 (6.7) 4 (13.3) 6 (10) 
Mitral valve replacement + 
Tricuspid annuloplasty (MVR + 
TRA) 
4 (13.3) 2 (6.7) 6 (10) 
Open Mitral Valvotomy (OMV) 1 (3.3) 0 1 (1.7) 
Total 30 (100) 30 (100) 60 (100) 
 
Chi-square value: 3.529            p value: 0.619  
 Comments: There was no statistically significant difference in 
proportion of various types of surgical procedures done between the two 
groups. 
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Fig 4: Distribution of the subjects according to surgical procedure (n=60) 
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Table 5: Distribution of the study groups according to duration of surgical 
procedure (n=60) 
Group N 
Mean 
duration 
(minutes) 
Std. 
Deviation 
Mean 
difference 
Student 
‘t’ test 
p value 
95% C.I 
IV 30 249.0 52.348 
-6.50 0.672 -37.10 to 24.10 
Oral 30 255.5 65.355 
 
Comments: 
 The difference in duration of surgical procedure between subjects in the 
two groups was not statistically significant and hence the groups were 
comparable. 
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Fig 5: Distribution of the study groups according to duration of  
surgical procedure (n=60) 
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Table 6: Distribution of the study groups according to pre-operative 
(baseline) parameters (n=60) 
Baseline 
Parameter 
Group Mean 
Std. 
Deviation 
Mean 
difference 
Student 
‘t’test 
p value 
Hemoglobin 
(gm/dl) 
IV 12.173 1.607 
0.006 0.988 
Oral 12.167 1.725 
Platelet 
count 
(lakhs/ul) 
IV 2.7030 0.8851 
-0.087 0.679 
Oral 2.7903 0.7350 
 
Comments: 
 There was no statistically significant difference in baseline hemoglobin 
and platelet count levels between the two groups and hence the groups were 
comparable. 
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fig 6: Distribution of the study groups according to pre-operative 
(baseline) haemoglobin (n=60) 
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Table 7: Distribution of the study groups according to pre-operative 
(baseline) parameters (n=60) 
 
Baseline 
Parameter 
Group Mean 
Std. 
Deviation 
Mean 
difference 
Student 
‘t’ test 
p value 
Activated 
clotting time 
IV 157.57 34.473 
17.80 0.016 
Oral 139.77 19.172 
Prothrombin 
time 
IV 13.497 2.7339 
-1.136 0.093 
Oral 14.633 2.4144 
INR 
IV 1.0883 0.2256 
-0.122 0.026 
Oral 1.2103 0.1868 
Bleeding 
Time 
IV 132.13 8.27 
-9.567 0.012 
Oral 141.70 18.41 
Clotting time 
IV 245.33 48.54 
-18.267 0.107 
Oral 263.60 37.16 
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Comments:  
1. There was no statistically significant difference in baseline prothrombin 
time and clotting time between the two groups. 
2. The difference in baseline activated clotting time, INR and bleeding 
time between the two groups was statistically significant. 
Fig 7: Distribution of the study groups according to pre-operative 
(baseline) platelet count (n=60) 
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Table 8: Distribution of the study groups according to intra-operative 
blood loss (n=60) 
Parameter Group Mean 
Std. 
Deviation 
Mean 
difference 
Student 
‘t’test 
p value 
Intra-op blood 
loss 
(ml) 
IV 678.33 286.08 
-64.33 0.406 
Oral 742.67 308.48 
 
Comments:  
 There was no statistically significant difference in intra-operative blood 
loss between the two groups. 
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Fig 8: Distribution of the study groups according to pre-operative 
(baseline) parameters (n=60) 
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TABLE 9: DISTRIBUTION OF THE STUDY GROUPS ACCORDING 
TO INTRA-OPERATIVE ACTIVATED CLOTTING  
TIME (ACT) (N=60) 
Parameter Group Mean Std. Deviation Mean difference 
Student 
‘t’test 
p value 
Intra-op ACT 
IV 160.70 29.038 
2.633 0.711 
Oral 158.07 25.637 
 
 
Comments:  
 There was no statistically significant difference in intra-operative 
activated clotting time between the two groups. 
 
42 
 
 
 
 
Fig 9: Distribution of the study groups according to intra-operative blood 
loss in ml (n=60) 
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Table 10: Distribution of the study groups according to need for intra-
operative blood transfusion (n=60) 
Group 
Blood transfusion 
Total 
n (%) 
Not needed 
n (%) 
Done 
n (%) 
I.V Group 13 (59.1) 17 (44.7) 30 (50) 
Oral Group 9 (40.9) 21 (55.3) 30 (50) 
Total 22 (100) 38 (100) 60 (100) 
 
Chi-square value: 1.148            p value:0.284 
Comments:  
 The difference in proportion of intra-operative blood transfusion 
between the groups was not statistically significant. 
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Fig 10: Distribution of the study groups according to need for intra-
operative blood transfusion (n=60) 
 
 
 
 
 
45 
 
 
 
Table 11: Distribution of the study groups according to units of blood 
transfused in the intra-operative period  (n=38) 
 
Intra-op 
Parameter 
Group N Mean Median IQR 
Mann-
Whitney test 
p value 
Units of 
blood 
transfused 
IV 17 1.29 1.0 1.0 to 2.0 
<0.001 
Oral 21 2.57 2.0 2.0 to 4.0 
 
Comments:  
 Among the subjects who needed blood transfusion in the intra-operative 
period, subjects in the oral group required roughly 1 unit of blood product over 
and above the subjects in intra-venous group and this difference was 
statistically significant 
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Fig 11: Distribution of the study groups according to need for intra-
operative blood transfusion (n=60) 
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Table 12: Distribution of the study groups according to post-operative 
drain volume (n=60) 
Parameter Group Mean 
Std. 
Deviation 
Mean 
difference 
Student 
‘t’test 
p value 
Post-op 
drain 
volume (ml) 
IV 362.00 188.577 
-14.667 0.746 
Oral 376.67 159.056 
 
Comments:  
 There was no statistically significant difference in post-operative drain 
volume between the two groups. 
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Fig 12: Distribution of the study groups according to need for post -
operative blood transfusion (n=60) 
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Table 13: Distribution of the study groups according to need for post-
operative blood transfusion (n=60) 
 
Group 
Post-op Blood transfusion 
Total 
n (%) 
Not needed 
n (%) 
Done 
n (%) 
I.V Group 27 (57.4) 3 (23.1) 30 (50) 
Oral Group 20 (42.6) 10 (76.9) 30 (50) 
Total 47 (100) 13 (100) 60 (100) 
 
Chi-square value: 4.812            p value: 0.028 
Comments:  
The difference in proportion of post-operative blood transfusion 
between the groups was statistically significant with more subjects in oral 
group requiring blood transfusion than the intra-venous group subjects. 
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Fig 13: Distribution of the study groups according to hemoglobin levels in 
the pre and post-operative period (n=60) 
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Table 14: Distribution of the study groups according to units of blood 
transfused in the post-operative period(n=13) 
Post-op 
Parameter 
Group N Mean Median IQR 
Mann-
Whitney test 
p value 
Units of 
blood 
transfused 
IV 3 1.33 1.0 
1.0 to 
2.0 
0.232 
Oral 10 1.90 2.0 
1.0 to 
2.25 
 
Comments:  
 Among the subjects who needed blood transfusion in the post-operative 
period, subjects in the oral group required roughly 1 unit of blood product over 
and above the subjects in intra-venous group but this difference was not 
statistically significant. 
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Fig 14: Distribution of the study groups according to platelet levels in the 
pre and post-operative period (n=60) 
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Table 15: Distribution of the study groups according to hemoglobin levels 
in the post-operative period  (n=60) 
Group 
Mean 
Hb 
(g/dl) 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
I.V 10.503 1.8365 9.818 11.189 
Oral 9.440 1.4373 8.903 9.977 
Total 9.972 1.7207 9.527 10.416 
 
ANCOVA test was applied to test the difference in mean hemoglobin 
levels in the post-operative period between the groups with baseline levels of 
hemoglobin as covariate. 
 
ANCOVA test 
Model Group Hb changes + Group 
F statistic 10.813 14.95 
Degree of freedom 1,56 1,56 
p value 0.002 0.001 
 
As there was statistically significant interaction in changes of Hb and 
the two groups, drop in Hb levels after surgery based on pre-surgery levels was 
analysed in each group separately. 
 
54 
 
 
Group 
Post-op mean 
Hb fall 
(g/dl) 
Std. 
Deviation 
Mean 
difference 
Student ‘t’ test 
p value 
I.V 1.670 0.6939 
1.0567 0.001 
Oral 2.727 1.5425 
 
Comments: 
Student ‘t’ test showed that there was statistically significant difference 
in mean fall of hemoglobin levels in the post-operative period with the 
hemoglobin fall being more in oral group than IV group. 
 
Fig 15: Distribution of the study groups according to bleeding time in the 
pre and post-operative period (n=60) 
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Table 16: Distribution of the study groups according to platelet levels in 
the post-operative period (n=60) 
Group 
Mean 
Platelet 
level 
(cells/µl) 
Std. 
Deviation 
95% Confidence Interval 
for Mean 
Lower 
Bound 
Upper 
Bound 
I.V 2.1510 0.81883 1.8452 2.4568 
Oral 2.1477 0.69483 1.8882 2.4071 
Total 2.1493 0.75290 1.9548 2.3438 
 
ANCOVA test was applied to test the difference in mean platelet levels 
in the post-operative period between the groups with baseline platelet levels in 
pre-operative period as covariate. 
 
ANCOVA test 
p value 0.289 
F statistic 1.147 
Degree of freedom 1,57 
 
Comments: 
ANCOVA test showed that there was no statistically significant 
difference in mean platelet levels in the post-operative period between the 
groups with baseline platelet levels in pre-operative period as covariate. 
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Fig 16: Distribution of the study groups according to clotting time in the 
pre and post-operative period (n=60) 
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Table 17: Distribution of the study groups according to bleeding time in 
the post-operative period (n=60) 
Group 
Mean 
BT 
(seconds) 
Std. Deviation 
95% Confidence Interval for 
Mean 
Lower 
Bound 
Upper Bound 
I.V 132.63 8.079 129.62 135.65 
Oral 142.47 16.328 136.37 148.56 
Total 137.55 13.701 134.01 141.09 
 
ANCOVA test was applied to test the difference in mean bleeding time 
in the post-operative period between the groups with baseline bleeding time in 
pre-operative period as covariate. 
 
ANCOVA test 
p value 0.188 
F statistic 1.779 
Degree of freedom 1,57 
 
Comments: 
ANCOVA test showed that there was no statistically significant 
difference in mean bleeding time in the post-operative period between the 
groups with baseline bleeding time in pre-operative period as covariate. 
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Fig 17: Distribution of the study groups according to prothrombin time in 
the pre and post-operative period (n=60) 
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Table 18: Distribution of the study groups according to clotting time in the 
post-operative period (n=60) 
Group 
Mean 
CT 
(seconds) 
Std. 
Deviation 
95% Confidence Interval 
for Mean 
Lower 
Bound 
Upper 
Bound 
I.V 250.00 41.206 234.61 265.39 
Oral 272.50 41.098 257.15 287.85 
Total 261.25 42.350 250.31 272.19 
 
ANCOVA test was applied to test the difference in mean clotting time in 
the post-operative period between the groups with baseline clotting time in pre-
operative period as covariate. 
 
ANCOVA test 
p value 0.181 
F statistic 1.838 
Degree of freedom 1,57 
 
Comments: 
ANCOVA test showed that there was no statistically significant 
difference in mean clotting time in the post-operative period between the 
groups with baseline clotting time in pre-operative period as covariate. 
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Fig 18: Distribution of the study groups according to INR in the pre and 
post-operative period (n=60) 
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Table 19: Distribution of the study groups according to prothrombin time 
in the post-operative period (n=60) 
Group 
Mean 
PT 
(seconds) 
Std. 
Deviation 
95% Confidence Interval 
for Mean 
Lower 
Bound 
Upper 
Bound 
I.V 13.330 2.2510 12.489 14.171 
Oral 14.440 2.6479 13.451 15.429 
Total 13.885 2.5000 13.239 14.531 
 
ANCOVA test was applied to test the difference in mean prothrombin 
time in the post-operative period between the groups with baseline prothrombin 
time in pre-operative period as covariate. 
 
ANCOVA test 
p value 0.644 
F statistic 0.216 
Degree of freedom 1,57 
 
Comments: 
ANCOVA test showed that there was no statistically significant 
difference in mean prothrombin time in the post-operative period between the 
groups with baseline prothrombin time in pre-operative period as covariate. 
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Fig 19: Distribution of the study groups according to activated clotting 
time in the Pre, Intra and Post-operative period (n=60) 
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Table 20: Distribution of the study groups according to INR in the post-
operative period (n=60) 
Group 
Mean 
INR 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
I.V 1.1190 .22293 1.0358 1.2022 
Oral 1.2277 .21282 1.1482 1.3071 
Total 1.1733 .22292 1.1157 1.2309 
 
ANCOVA test was applied to test the difference in mean INR in the 
post-operative period between the groups with baseline INR in pre-operative 
period as covariate. 
 
ANCOVA test 
p value 0.723 
F statistic 0.127 
Degree of freedom 1,57 
 
Comments: 
ANCOVA test showed that there was no statistically significant 
difference in mean INR in the post-operative period between the groups with 
baseline INR in pre-operative period as covariate. 
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Fig 20: Comparison of need for intra-operative blood transfusion among 
subjects with surgery duration of above 5 hours (n=17) 
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Table 21: Comparison of pre-operative and post-operative parameters in 
the IV group (n=30) 
Parameter in 
IV group 
Group Mean 
Std. 
Deviation 
Mean 
difference 
Paired ‘t’ test 
p value 
Hemoglobin 
Pre-op 12.173 1.6071 
1.67 <0.001 
Post-op 10.503 1.8365 
Platelet count 
Pre-op 2.7030 .88514 
0.55200 <0.001 
Post-op 2.1510 .81883 
Activated 
clotting time 
Pre-op 157.57 34.473 
7.533 0.271 
Post-op 150.03 13.116 
INR 
Pre-op 1.0883 .22563 
-0.03067 0.147 
Post-op 1.1190 .22293 
Prothrombin 
time 
Pre-op 13.497 2.7339 
0.1667 0.476 
Post-op 13.330 2.2510 
Bleeding 
Time 
Pre-op 132.13 8.270 
-0.500 
 
0.530 
Post-op 132.63 8.079 
Clotting time 
Pre-op 245.33 48.547 
-4.667 0.381 
Post-op 250.00 41.206 
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Comments:  
1. There was no statistically significant difference between pre-operative 
and post-operative levels of Activated clotting time, prothrombin time, 
INR, Bleeding Time and clotting time in the IV group 
2. However, the difference between pre-operative and post-operative levels 
of Hemoglobin and Platelet count among the subjects in IV group was 
statistically significant. 
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Fig 21: Comparison of need for post-operative blood transfusion among 
subjects with surgery duration of above 5 hours (n=17) 
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Table 22: Comparison of pre-operative and post-operative parameters in 
the oral group (n=30) 
Parameter in 
Oral group 
Group Mean 
Std. 
Deviation 
Mean 
difference 
Paired 
‘t’test 
p value 
Hemoglobin 
Pre-op 12.167 1.7257 
2.7267 <0.001 
Post-op 9.440 1.4373 
Platelet count 
Pre-op 2.7903 .73509 
0.64267 <0.001 
Post-op 2.1477 .69483 
Activated 
clotting time 
Pre-op 139.77 19.172 
-20.633 <0.001 
Post-op 160.40 10.711 
INR 
Pre-op 1.2103 .18683 
-0.01733 0.617 
Post-op 1.2277 .21282 
Prothrombin 
time 
Pre-op 14.633 2.4144 
0.1933 0.253 
Post-op 14.440 2.6479 
Bleeding Time 
Pre-op 141.70 18.417 
-0.767 0.664 
Post-op 142.47 16.328 
Clotting time 
Pre-op 263.60 37.160 
-8.900 <0.001 
Post-op 272.50 41.098 
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Comments:  
1. There was no statistically significant difference between pre-operative 
and post-operative levels of, prothrombin time, INR, and Bleeding Time 
in the oral group 
2. However, the difference between pre-operative and post-operative levels 
of Haemoglobin, Platelet count, Activated clotting time and clotting 
time among the subjects in Oral group was statistically significant. 
  
70 
 
 
Table 23: Comparison of pre-operative, intra-operative and post-operative 
activated clotting time (n=60) 
Activated clotting 
time 
Group Mean Std. Deviation N 
Pre-op 
IV 157.57 34.473 30 
Oral 139.77 19.172 30 
Total 148.67 29.075 60 
Intra-op 
IV 160.70 29.038 30 
Oral 158.07 25.637 30 
Total 159.38 27.189 60 
Post-op 
IV 150.03 13.116 30 
Oral 160.40 10.711 30 
Total 155.22 12.972 60 
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Repeated measures ANOVA was applied to test the difference in mean 
activated clotting time at various time intervals between the two groups. 
 
Model Changes in ACT over time ACT changes + Group 
Wilks’s Lambda 2.198 7.609 
p value 0.120 0.001 
 
As there was statistically significant interaction in changes of ACT and 
the two groups, ACT levels at various time periods was analysed in each 
group separately. 
 
Group I.V Oral 
Wilks’s Lambda 2.014 16.496 
p value 0.152 <0.001 
Partial Eta square 12.6% 54.1% 
 
Post-Hoc Test for oral group (n=30) 
 
Comparison Group Mean difference p value 
Pre-op ACT vs Intra-op ACT -18.30 0.041 
Intra-op ACT vs Post-op ACT -2.33 1.00 
Pre-op ACT vs Post-op ACT -20.63 <0.001 
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Comments: 
1. Repeated measures ANOVA test showed that the changes in 
mean activated clotting time at various time intervals was 
statistically significant only in the oral group but not in the I.V 
group. 
2. Post-hoc tests in the oral group revealed that rise in mean ACT in 
the intra-op and post-op period when compared to pre-op levels 
was statistically significant. 
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Table 24: Comparison of need for intra-operative blood transfusion 
among subjects with surgery duration of above 5 hours (n=17) 
Group 
Blood transfused 
n (%) 
No transfusion 
n (%) 
Total 
n (%) 
IV group 2 (15.4) 4 (100) 6 (35.3) 
Oral group 11 (84.6) 0 11 (64.7) 
Total 13 (100) 4 (100) 17 (100) 
 
Chi-square value: 6.242             p value:0.012 
For volume of units transfused between 2 groups: 
 Mann Whitney U testp value: 0.102 
 Comments:  The difference in distribution of intra-operative blood 
transfusion among subjects with surgery duration of above 5 hours was 
statistically significant with all the subjects in oral group Compared to one-
third of the subjects in IV group requiring blood transfusion. But the number of 
units required among those who needed transfusion was not significant. 
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Table 25: Comparison of need for post-operative blood transfusion among 
subjects with surgery duration of above 5 hours (n=17) 
Group 
Blood transfused 
n (%) 
No 
transfusion 
n (%) 
Total 
n (%) 
IV group 1 (11.1) 5 (62.5) 6 (35.3) 
Oral group 8 (88.9) 3 (37.5) 11 (64.7) 
Total 9 (100) 8 (100) 17 (100) 
Chi-square value: 4.898             p value:0.027 
For volume of units transfused between 2 groups: 
Mann Whitney U testp value: 0.131 
Comments: 
 The difference in distribution of post-operative blood transfusion among 
subjects with surgery duration of above 5 hours was statistically significant 
with more (89%) subjects in oral group requiring blood transfusion compared 
to 11% of the subjects in IV group. But the number of units required among 
those who needed transfusion was not significant. 
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Table 26: Comparison of pre-operative and post-operative hemoglobin 
levels among subjects with surgery duration of above 5 hours (n=17) 
Group Parameter Mean Hb 
Std. 
Deviation 
Mean Hb 
drop 
Paired 
‘t’test 
p value 
Oral group 
(n=11) 
Pre-op Hb 11.527 1.4711 
3.1091 <0.001 
Post-op Hb 8.418 1.2164 
IV group 
(n=6) 
Pre-op Hb 12.550 1.9857 
1.966 <0.001 
Post-op Hb 10.583 2.3319 
 
Comments:  
 There was a statistically significant difference (reduction) between pre-
operative and post-operative levels of hemoglobin in both the groups. 
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Table 27: Comparison of reduction in hemoglobin levels among subjects 
with surgery duration of above 5 hours (n=17) 
Group N 
Mean Hb 
reduction 
(preop-postop) 
Std. 
Deviation 
Mean 
difference 
in Hb drop 
Student 
‘t’test 
p value 
Oral 11 3.109 0.8619 
1.1424 0.012 
IV 6 1.967 0.6022 
 
Comments:  
 There was a statistically significant difference between the two groups 
regarding the post-operative drop in Hemoglobin levels as the subjects in the 
oral group had roughly 1 gm greater reduction in hemoglobin in comparison to 
IV group. 
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DISCUSSION 
 Blood loss is of main concern in major surgeries. The reason being 
anemia poses severe threat to life since hemoglobin is the main carrier of 
oxygen in blood. 
Oxygen content = (Hb x 1.34 x SaO2)+ (0.003 x PaO2) 
 Decrease in oxygen content does not manifest initially till a critical level 
and this occurs because of the sigmoid shape of oxygen dissociation curve 
(cooperative binding of hemoglobin towards oxygen). 
OXYGEN DISSOCIATION CURVE: 
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 In a healthy individual, anemia is compensated by increasing the cardiac 
output to maintain the oxygen delivery to the tissues(oxygen flux). 
Oxygen flux = cardiac output x oxygen content 
 Diseased heart would be unable to increase its output and hence would 
eventually fail. Thus, avoiding and treating anemia is of prime importance in 
cardiac patients. It can be done by either limiting the blood loss or by 
transfusing blood products. 
 Transfusing blood has its own demerits ranging from a mere febrile 
transfusion reaction, itching, rashes to a full blown anaphylaxis, TRALI 
(Transfusion Related Acute Lung Injury), blood borne infections which 
includes but not limited to malaria, HIV, Hepatitis B & C. Hence avoiding or 
limiting the amount of blood transfusions would be the ideal way to avoid the 
complications. 
 Then came the concept of blood conservation techniques. SABM 
(Society for Advanced Blood Management) team aims at using the latest drugs, 
technology & techniques to reduce and avoid the need for transfusions. 
METHODS TO REDUCE BLOOD TRANSFUSIONS IN SURGERY: 
 PRE-OPERATIVE: 
o In elective surgery- correct hemoglobin. Stop drugs interfering 
with hemostasis 
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 INTRA OPERATIVE: 
o Posture 
o Use vasoconstrictors 
o Torniquets 
o Antifibrinolytic drugs: Tranexamic acid 
o Controlled hypotension 
 POST OPERATIVE: 
o Blood salvage techniques to reinfuse blood from drains. 
 
Blood conservation techniques used nowadays include: 
 Acute normovolemic hemodilution 
 Hemodilution with crystalloid solution 
 Intraop autologous donation 
 Cell saver 
 Apheresis/ platelet gel/ PRP 
 Ultrafiltration (hemoconcentration), hemobag 
 Autotransfusion of unprocessed shed blood from chest tube collection 
drain. 
Cardiac surgeries involve dealing with heart and the major blood 
vessels. Thus, they have high potency for massive blood loss. 
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Fig. CARDIOPULMONARY BYPASS 
 
Further, these patients are subjected to cardiopulmonary bypass wherein 
the blood is diverted out of the person’s body, oxygenated and pumped back 
into the aorta from where it goes into the systemic circulation in a non-pulsatile 
fashion. 
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Fig. PRINCIPLES GOVERNING CARDIOPULMONARY BYPASS 
 
Cardiopulmonary bypass has the following components and along with their 
clinical implications are enlisted as follows: 
1. Pump consists of 2 roller head that compresses the tubings of bypass 
circuit. As it rotates, it propels fluid in the same direction as rotations 
while fluid is sucked behind the occlusive point.  
The volume of fluid pumped out depends on: 
 Volume of tubing occluded by the roller 
 Number of revolutions made by the roller. 
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2. The pump has to be placed before membrane oxygenators because 
they are high resistant circuits and hence need higher force to push it 
through the oxygenator. 
 
3. Occlusion setting in pump head is most important to reduce the 
hemolysis. It should be set at the maximum in cardioplegia and 
venting to avoid air entrainment. 
 
4. The roller pumps are set at constant flow and hence they continue to 
deliver the set volume regardless of resistance. The line pressures 
have to be maintatined less than 250mmHg.  
 
5. The circuit is primed with fluid before bypass. The concept of 
priming is: 
 To avoid gas embolism and  
 Perfusion improves when there is drop in viscosity 
 Reduced neurological, renal and pulmonary complications.  
 
Prime volume is the volume required to de-air the circuit. And prime is 
the cause of hemodilution in CPB. This drop in viscosity increases the cardiac 
output. Thus the overall oxygen delivery to the tissues that we discussed 
earlier, may not be significantly affected even when the oxygen carrying 
capacity is reduced. Haemoglobin of 6-7g is considered reasonable in CPB. 
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Higher haemoglobin is justified when the patient has associated significant risk 
factors like Cerebro Vascular Accidents, Diabetes mellitus, cardiovascular 
diseases, carotid stenosis.  
Predicted hematocrit =     (patient blood volume x hematocrit)   /  
(patient blood volume + prime) 
Patient’s blood volume  =  75 x weight (in kg) 
 
 Addition of crystalloid alone leads to drop in colloid oncotic pressure 
and hence tissue edema. Thus mannitol, albumin have been used along with the 
prime to avoid interstitial edema. Balanced lactated ringer is the most 
commonly used primer. An adult circuit needs around 1.5 to 2litres initially. 
 
CLINICAL APPLICATION: 
The blood is subjected to mechanical trauma in the rotors and hence 
there is potential space for mechanical damage to red blood cells and platelets. 
This may lead to increased blood loss postoperatively because of ineffective 
platelet plug formation. Furthermore there is dilution of blood because of 
addition of primer fluid of about 1 to 1.5litres. In our institute, tranexamic acid 
is used regularly for all open-heart surgeries to reduce blood loss. Tranexamic 
acid decreases fibrinolysis and hence helps form organized clot. 
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Ethamsylate helps reduce capillary bleeding especially when associated 
with plateletdysfunction.  Ethamsylate was also thought to stabilise capillaries, 
reinforcing capillary membranes by polymerising hyaluronic acid[1]. 
Combination of tranexamic acid and ethamsylate have been used with good 
success in treating menorrhagia[2]. They have been testing in various surgeries 
including ENT, ophthalmic, urogenital, dental and general surgeries with 
positive results.  
 
INFLAMMATORY MEDIATORS IN CARDIOPULMONARY BYPASS 
AND CLINICAL SIGNIFICANCE[29-32]: 
 Inflammation is the normal protective response of the body towards 
antigens or tissue injury. When this occurs in the body as a whole, it can lead to 
severe problems like: 
 Severe organ dysfunction 
 Post operative bleeding disorders 
 Respiratory distress syndrome 
 Death (rarely). 
 
In cardiopulmonary bypass it is attributed to: 
 blood interfacing with non-endothelial surfaces of the circuits of CPB 
 Ischaemia and reperfusion following release of aortic cross clamp. 
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Inflammatory response consists of: 
 Activation of complement system 
 
 Activation of tissue macrophage and monocytes – releasing cytokines 
and other inflammatory mediators 
 
 Activation of neutrophils and enzyme release. 
 
 Leucocyte migration and accumulation in tissues 
 
 Increased vascular permeability. 
 
Cytokines are a class of chemoattractants synthesized by macrophages. 
Interleukins are a group of cytokines which produce inflammation by action on 
receptors of inflammatory cells and vasculature. 
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Following a extensive tissue injury, systemic inflammatory response is 
elicited. This manifests as fever, anorexia, synthesis of acute phase reactants. 
This response following a cardiac surgery is termed as “post perfusion 
syndrome”.  
The inflammatory response to cardiopulmonary bypass influences the 
outcome as they bleed more, require respiratory support, have greater capillary 
leak.  
 
 In our study, Both the groups were comparable in terms of age, number 
of valves involved, proportion of the types of surgical procedures done and the 
duration of surgical procedure. There were more females in intravenous group 
than in oral group and this was statistically significant. 
 
 In the baseline parameters, hemoglobin, platelet counts, prothrombin 
time and clotting time were comparable while the difference in ACT, INR, and 
the bleeding time were statistically significant. 
 
 Intraoperative figures showed that the blood loss and the blood 
transfusions in both the groups were comparable. The ACT values were also 
comparable hence proving that both the drugs have very minimal to nil effects 
on the clotting parameters. Intraoperatively, Oral group needed transfusions 
required roughly 1 unit of blood product more than intravenous group and this 
was statistically significant. 
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 Post operatively, the drain in both the groups were comparable.  
 There was a significant difference in transfusion requirements in both 
the groups with the oral group requiring roughly one blood product more than 
the intravenous group though the quantity was notstatistically significant. We 
could infer that the oral group requires either oral or IV supplementation post 
operatively to reduce the post op transfusion requirements.And when both 
these groups were compared with respect to duration > 5hours, all the subjects 
in oral group compared to one-third of the subjects in IV grouprequired blood 
transfusion. Hence, we conclude that with the passage of time oral group 
requires additional intravenous supplementation of drugs to prolong the effects.   
 ANCOVA test was applied to test the difference in mean hemoglobin, 
platelets, PT, INR bleeding time, and clotting time in the post-operative period 
between the groups with baseline levels as covariate.ANCOVA test showed 
that there was no statistically significant difference in mean platelet levels, PT, 
INR, bleeding time and clotting time in the post-operative period between the 
groups. 
 Student ‘t’ test showed that there was statistically significant difference 
in mean fall of hemoglobin levels in the post-operative period with the 
hemoglobin fall being more in oral group than IV group.  And on comparing 
the reduction in hemoglobin levels among subjects with surgery duration of 
above 5 hours,there was a statistically significant reductionbetween pre-
operative and post-operative levels of hemoglobin in both the groups.Further, 
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the subjects in the oral group had roughly 1 gm greater reduction in 
hemoglobin in comparison to IV group. 
 The difference in distribution of post-operative blood transfusion among 
subjects with surgery duration of above 5 hours was statistically significant 
with more (89%) subjects in oral group requiring blood transfusion compared 
to 11% of the subjects in IV group. But the number of units required among 
those who needed transfusion was not significant  
  
 
 
SUMMARY 
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SUMMARY 
This study was conducted to compare the efficacy of oral and 
intravenous formulations of tranexamic acid and ethamsylate combination in 
controlling bleeding in patients undergoing cardiopulmonary bypass. 
The following results were obtained from our study: 
The blood loss in both the groups were comparable. 
The blood transfusions in both the groups were comparable. 
The intra-operative ACT values were comparable hence proving that 
both the drugs have very minimal to nil drug interactions with heparin. 
Intraoperatively, Oral group needed transfusions required roughly 1 unit 
of blood product more than intravenous group.  
When groups were compared with respect to duration > 5hours, all the 
subjects in oral group compared to one-third of the subjects in IV group 
required blood transfusion. Hence, we conclude that oral group requires 
additional intravenous supplementation of drugs to prolong the effects when 
duration is more than 5hours. 
 Post operatively, in patients whose surgery duration of above 5 hours 
showed 89%subjects in oral group requiring blood transfusion compared to 
11% of the subjects in IV group. 
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 Statistically significant difference in mean fall of hemoglobin levels in 
the post-operative period with the hemoglobin fall being more in oral group 
than IV group. 
 On Comparing the reduction in hemoglobin levels among subjects with 
surgery duration of above 5 hours,there was a statistically significant reduction 
between pre-operative and post-operative levels of hemoglobin in both the 
groups with the oral group having roughly 1 gm greater reduction in 
hemoglobin in comparison to IV group. 
 There were no statistically significant difference in mean platelet levels, 
PT, INR, bleeding time and clotting time in the post-operative period in 
comparison with baseline between the groups and hence we can infer that there 
is almost nil effect on other bleeding or clotting parameters by both the drugs. 
 
  
 
 
CONCLUSION 
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CONCLUSION 
 In conclusion, this study indicated that both intravenous and oral 
formulations of the combination were equally efficacious in controlling blood 
loss and decreasing the transfusion requirements in patients undergoing 
cardiopulmonary bypass, provided the duration of the surgery is within the 
plasma half life of the drugs. 
 
 In case of exceeding the plasma half life, additional doses or adopting 
methods like cell salvage methods may help reduce the blood loss and 
transfusions. 
 
 Oral formulation is found to be cost effective than intravenous 
formulation.
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ANNEXURES 
  
ANNEXURES 
PROFORMA 
TITLE: 
PROSPECTIVE RANDOMISED COMPARATIVE STUDY OF 
EFFICACY OF COMBINATION OF TRANEXAMIC ACID AND 
ETHAMSYLATE BY ORAL AND INTRAVENOUS ROUTES IN 
RELATION TO CONTROL OF BLEEDING IN  
CARDIAC SURGERIES. 
 
DATE:                              IP NO:                    
NAME:  
AGE:                      SEX:                         
DIAGNOSIS: 
SURGICAL PROCEDURE: 
Ht:                                           CVS:                                 
Wt:                                           RS:                             
PRE OP ASSESSMENT:                                       HB:                    BT/CT: 
       AIRWAY:                                                       PLATELET COUNT: 
                                                                                ACT: 
HISTORY:  
   Any Co-morbid illness 
   H/O Documented Difficult Airway 
   H/O previous surgeries 
INFORMED CONSENT IN TAMIL: 
RANDOMIZATION: Tick the following 
                                    1) GROUP O 
                                    2) GROUP I 
IV line 
PREMEDICATION 
MONITORS 
BASELINE VITAL PARAMETERS 
Heart rate  
IBP  
SpO2  
Hb  
MEASURES OF PRIMARY OUTCOME AND SECONDARY 
OUTCOME 
INTRA –OPERATIVE   
 Heart Rate 
 Non-invasive BP, Invasive BP. 
 SPO2 
 Respiratory rate 
 Central venous pressure 
 Volume of blood collected in suction apparatus 
 Partial/complete blood soaked gauze counts(3 / 5ml )  
 Partial / complete blood soaked pads counts (30 / 50 ml)  
 Change in hematocrit after surgery 
 Change in BT,  CT,  platelet count after surgery 
 HR,  BP,  SpO2,  Urine output 
 Postoperative drain collected 
 
END OF SURGERY: 
ACT No of Soaked 
Pads 
No. of Soaked 
Gauze 
Suction 
Collection 
Blood 
Transfusion 
(Yes / No) 
     
 
 
 
 
POST OP BLOOD LOSS ASSESSMENT (24HRS AFTER SURGERY) 
Suction Drain 
Blood 
Transfusion 
Hematocrit BT / CT Platelet Count 
     
 
  
INFORMATION TO PARTICIPANTS 
Investigator                     :  Dr HEMALATHA R V 
Name of the Participant: 
Title:  
“PROSPECTIVE RANDOMISED COMPARATIVE STUDY OF 
EFFICACY OF COMBINATION OF TRANEXAMIC ACID AND 
ETHAMSYLATE BY ORAL AND INTRAVENOUS ROUTES IN 
RELATION TO CONTROL OF BLEEDING IN CARDIAC 
SURGERIES.” 
 
You are invited to take part in this research study. We have got approval 
from the Institutional Ethical Committee. You are asked to participate because 
you satisfy the eligibility criteria. We want to compare between oral and 
intravenous formulations of tranexamic acid and ethamsylate and study their 
effectiveness in reducing intra op and postoperative blood loss in patients 
undergoing cardiac valve replacement surgeries.  
 
What is the Purpose of the Research: 
To know the effect of tranexamic acid in reducing intraoperative and 
postoperative blood loss in patients undergoing cardiac valve replacement 
surgeries. 
The secondary purpose of the study is 
1. To know the requirement of transfusion intra-operatively and post -  
      operatively.  
2. To study the effect of drug on hematocrit change after surgery. 
  
The Study Design: 
Total number of patients 60. All undergoing cardiac valve replacement 
surgeries. 
Group 1- Group- O - Oral ethamsylate and Oral tranexamic acid. 
Group2-Group- I - Intravenous ethamsylate and Intravenous tranexamic acid. 
 
Benefits: 
 Intra operative and post operative blood loss reduction. 
 Decreased transfusion requirements and transfusion related hazards.  
Discomforts and risks:  
 Allergy to tranexamic acid and ethamsylate.  
 
This intervention has been shown to be well tolerated as shown by 
previous studies. And if you do not want to participate you will have an 
alternative setting of the standard treatment and your safety is our prime 
concern. 
 
Time : 
Date :                                        Signature / Thumb Impression of the patient 
Place   : 
                                   Patient Name: 
Signature of the Investigator : ____________________________ 
Name of the Investigator      : _______________________ 
  
PATIENT CONSENT FORM 
Study title : 
PROSPECTIVE RANDOMISED COMPARATIVE STUDY OF 
EFFICACY OF COMBINATION OF TRANEXAMIC ACID AND 
ETHAMSYLATE BY ORAL AND INTRAVENOUS ROUTES IN 
RELATION TO CONTROL OF BLEEDING IN CARDIAC 
SURGERIES.” 
 
Study centre : 
Institute of Anaesthesiology and Critical Care, 
Rajiv Gandhi Govt. General Hospital, 
Madras Medical College, 
Chennai- 600003 
 
  Participant name:                         I.P. No:                          Age:            Sex:              
          I confirm that I have understood the purpose of  procedure for the above  
study.  I have the opportunity to ask the question and all my questions and 
doubts have been answered to my satisfaction. 
 
         I have been explained about the pitfalls in the procedure.  I have been 
explained about the safety, advantage and disadvantage of the technique. 
 
          I understand that my participation in the study is voluntary and  that I am 
free to withdraw at anytime without giving any reason. 
 
          I understand that my identity will not be revealed in any information 
released to any third party or published, unless as required under the law . I 
agree not to restrict the use of any data or results that arise from the study. I 
hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical, radiological tests. 
 
                      I hereby agree to participate in this study. 
 
Time:         
Date:                                                Signature/thumb impression of patient 
 
Place:                                                                         Patient name: 
 
 
Signature of the investigator: 
 
Name of the investigator: 
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IV 48 Female RHD/ AS/ AR AVR 260 12.7 2.6 208 17.6 1.4 136 230 550 247 YES 1 400 NO 0 12 2.1 134 240 16.9 1.5 167 1
IV 60 Male RHD/ MS/ TR MVR 260 12.2 2.8 120 13 1.2 138 210 600 160 YES 1 400 NO 0 11 2.3 142 230 13.2 1.24 155 1.1
IV 43 Female RHD/ MS/ MR MVR 250 12.8 2.63 170 11.3 0.93 129 210 650 168 YES 1 600 NO 0 12 2.15 125 220 11.4 1.1 134 0.8
IV 55 Male RHD/ AS AVR 250 12.3 2.54 142 13 1.3 123 330 1100 144 YES 2 250 NO 0 10 2.1 115 342 13.5 1.5 154 2.1
IV 45 Male RHD/ POST CMC/ MS MVR 240 15 2.17 185 11.5 0.9 142 200 500 150 NO 0 250 NO 0 14 1.73 140 210 11.5 0.8 155 1
IV 57 Male SEVERE AS AVR 240 10.7 2.2 152 11 1.02 135 220 800 167 YES 2 400 NO 0 10 1.8 140 230 12 1.1 167 0.3
IV 40 Female RHD/ MS/AF MVR 230 13.6 2.34 150 20.3 1.5 120 230 800 130 NO 0 300 NO 0 11 1.8 130 260 14.1 1.4 143 2.6
IV 47 Female RHD/ MS MVR 230 11.1 3.1 140 10.7 0.89 132 250 350 155 NO 0 300 NO 0 9.2 1.97 135 260 10.7 0.92 156 1.9
Pre-op Intra-op Post-op
IV 42 Male RHD/ MS MVR 230 10.2 3.9 128 18.2 1.3 130 210 300 162 YES 1 100 NO 0 9.1 3.1 120 235 18.2 1.2 124 1.1
IV 52 Female RHD/ AS/ AR AVR 220 14.6 3.47 135 13.2 1.1 126 240 450 182 YES 1 300 NO 0 13 2.8 130 260 13.6 1 156 1.6
IV 32 Female RHD/ AS/ AR AVR 220 11.7 3.71 107 12 0.99 144 300 500 130 NO 0 200 NO 0 9.6 4.1 140 300 12.1 1.1 176 2.1
IV 52 Female RHD/ MS/ MR MVR 220 10.9 2.26 253 9.8 0.82 126 280 1600 160 YES 2 450 NO 0 9.2 1.75 128 292 9.7 0.87 145 1.7
IV 36 Female RHD/ MS/ TR/ LA CLOT OMV 220 9.8 2.16 248 7.6 0.65 126 310 600 162 NO 0 350 NO 0 8.1 1.76 128 317 8.2 0.7 156 1.7
IV 40 Female POST CMC/ MS MVR 210 14.1 2.92 138 14.1 1.1 110 320 900 171 YES 1 250 NO 0 13 1.98 120 220 15 1.1 145 1.2
IV 37 Male RHD/ MS/PCMC STATE MVR 210 13.7 2.05 126 15.1 1.28 130 220 1200 100 YES 2 1100 YES 1 13 1.09 128 240 14.8 1.32 134 0.9
IV 38 Male RHD/ MS/ TR MVR 210 13.6 2.8 180 15 1.1 128 260 900 168 YES 1 400 NO 0 12 2.4 130 260 15.1 1.17 145 1.7
IV 55 Female RHD/ MS/ SEVERE MVR 210 11.8 1.95 130 15.7 1.2 134 240 700 149 YES 1 350 NO 0 11 1.45 136 240 15.6 1.23 156 1.3
IV 53 Female RHD/ MS/ AR MVR 210 11.8 5.42 140 15.2 1.4 132 230 600 198 YES 1 450 NO 0 8 4.29 130 247 14.8 1.5 155 3.8
IV 55 Female RHD/ AS/ AR AVR 210 11 3.23 152 14.1 1 132 260 1000 162 YES 1 150 NO 0 9.8 2.87 134 260 13.9 1.2 143 1.2
IV 35 Male MVP/ MR/ CCF MVR 210 10.9 1.3 165 16.3 1.17 140 210 400 169 NO 0 550 YES 1 8.8 0.9 144 214 15.8 1.32 132 2.1
IV 60 Female RHD/ AS AVR 200 10.1 2.3 150 14.2 1.3 132 190 600 174 NO 0 250 NO 0 8.1 1.9 132 211 13.2 1.4 165 2
IV 35 Female RHD/ MS MVR 200 10 2.7 208 9.8 0.82 130 310 400 150 YES 2 450 NO 0 8.5 2.2 128 310 10.2 0.92 155 1.5
IV 34 Female RHD/ MS/ MR/ TR/ PHT MVR 190 11.6 2.28 160 14.8 0.9 123 190 450 158 NO 0 260 NO 0 9.6 1.99 125 195 14.9 0.92 135 2
Oral 44 Male RHD/MS/AR DVR 410 10.1 2.4 182 11.6 0.9 165 330 1550 101 YES 4 200 YES 2 7.3 1.92 155 320 10.6 0.9 155 2.8
Oral 58 Male RHD/ AS/ AR AVR 400 10.2 1.8 132 18.5 1.5 148 235 800 180 YES 4 700 YES 2 7.2 1.1 143 245 19.5 1.6 170 3
Oral 32 Female RHD/ AS/ AR/ MR DVR 360 10.2 2.22 134 12.4 1.02 167 250 800 168 YES 4 500 YES 3 7.2 1.7 160 234 11.1 1.1 156 3
Oral 37 Male RHD/MS/AR/TR DVR 340 13.7 2.9 120 15.5 1.3 134 280 700 154 YES 2 500 YES 1 9.1 1.8 144 299 16.5 1.4 165 4.6
Oral 36 Female RHD/MS/MR/TR MVR + TRA 320 11.3 2.2 142 12.6 1.1 125 250 1000 151 YES 3 600 YES 2 9.1 2.4 132 267 12.4 1.1 167 2.2
Oral 53 Male RHD/ MS MVR 315 13.8 3.85 140 14.5 1.2 148 238 1000 160 YES 4 300 YES 2 11 3.2 135 245 14.5 1.4 156 2.5
Oral 50 Male SEVERE MS MVR 310 12.5 2.8 120 18.1 1.5 110 240 1200 146 YES 3 400 YES 2 8.4 2.6 115 234 18 1.3 154 4.1
Oral 24 Female RHD/ MS/ MR/ TR MVR + TRA 300 12.5 2.7 128 14.9 1.2 106 200 900 165 YES 3 200 NO 0 8.7 1.3 110 198 14.9 1 156 3.8
Oral 54 Male SEVERE AS AVR 300 12.2 2.8 140 15.1 1.28 154 340 1200 174 YES 3 400 NO 0 8.5 2.5 167 339 14.5 1.2 165 3.7
Oral 60 Female RHD/ MS/ MR/ AR DVR 300 10.2 1.9 150 17.8 1.3 125 220 800 178 YES 4 400 NO 0 8.5 1.5 135 218 15.8 1.3 187 1.7
Oral 40 Male RHD/ AS/ AR AVR 300 10.1 2.4 182 11.6 0.9 154 300 550 101 YES 2 200 YES 3 7.3 1.92 150 324 11.6 0.8 176 2.8
Oral 37 Male RHD/ AS/ AR AVR 250 12.7 2.6 128 17.6 1.4 156 320 550 247 YES 1 400 NO 0 9.5 2.1 167 340 17.4 1.6 144 3.2
Oral 35 Male POST CMC/ MS MVR 250 11.2 2.2 120 13.2 1.17 145 300 400 168 NO 0 300 NO 0 11 1.8 156 329 13.3 0.9 160 0.7
Oral 25 Male BICUSPID AORTIC VALV AVR 220 14.5 3.1 155 11.2 1 154 300 700 162 NO 0 350 NO 0 9.7 2.3 145 328 11.2 1.3 165 4.8
Oral 40 Male RHD/ AR AVR 220 14.2 4.8 120 14.5 1.4 154 240 300 160 NO 0 150 NO 0 12 4.1 150 254 13.2 1.3 156 2
Oral 47 Male RHD/ MS MVR 220 14.1 3.9 139 12.8 1.1 145 300 600 187 YES 2 200 NO 0 11 3.2 155 312 11.4 1.3 155 3.6
Oral 47 Male POST CMC/ MR MVR 210 15.6 3.68 107 18.1 1.4 155 320 500 149 NO 0 700 NO
#N
UL
L!
10 2.89 144 335 17.1 1 155 5.5
Oral 25 Female RHD/ MS MVR 210 14.1 3.5 125 15.5 1.3 152 240 400 130 NO 0 400 NO 0 11 2.5 138 248 15.5 1.4 154 3
Oral 45 Male RHD/ AS/ AR AVR 210 13.3 3.5 159 12.5 1.3 145 240 500 133 YES 1 350 NO 0 11 2.6 142 250 12.3 1.3 155 2.1
Oral 55 Female RHD/ MS/ MR/ AF MVR 210 12.6 2.6 116 11.8 0.9 175 280 700 153 YES 1 200 NO 0 10 1.9 165 278 12.1 1.02 165 2.4
Oral 23 Male AR AVR 210 12.6 1.85 150 13.2 1.12 155 300 1500 147 YES 4 500 NO 0 9.2 1.3 158 312 12.8 1.41 156 3.4
Oral 32 Female RHD/ MR MVR 210 11.3 2.3 149 18.3 1.55 119 250 580 158 NO 0 450 NO 0 8.9 1.4 133 244 20.4 1.3 134 2.4
Oral 51 Male RHD/ AS/ AR AVR 210 11.2 2.2 120 10.8 1.2 148 230 600 168 NO 0 400 NO 0 9.6 1.6 143 243 11.8 1.5 154 1.6
Oral 60 Male RHD/ MS/ MR MVR 210 10.5 2.5 132 18.2 1.4 145 245 600 154 YES 2 700 YES 1 7.1 1.7 125 255 18.2 1.4 145 3.4
Oral 30 Female RHD/ MS/AF MVR 200 12.1 2.9 145 15.1 1.1 135 280 450 158 NO 0 400 NO 0 11 2.1 145 297 12.8 1.4 165 1
Oral 51 Male RHD/ SEVERE MS MVR 200 9.8 1.9 160 16.2 0.9 105 230 900 148 YES 2 400 NO
#N
UL
L!
8 1.3 104 255 16.4 0.9 165 1.8
Oral 28 Male RHD/ MS/ AR MVR 195 15.6 3.68 145 15.8 1.3 135 220 500 157 NO 0 300 NO 0 9.5 2.9 145 240 15.7 1 176 6.1
Oral 55 Male RHD/ MS/ MR MVR 195 12.1 2.9 140 13.8 1.3 150 240 700 158 YES 2 300 NO 0 10 2.2 155 234 13.9 1.3 177 1.8
Oral 38 Male RHD/SEVERE MR MVR 190 10.5 2.1 178 15.2 1.2 108 250 500 152 YES 1 300 YES 1 10 1.7 115 244 15.4 1.2 157 0.2
Oral 49 Female SEVERE AS/ MODERATE AVR 190 10.2 3.53 135 12.6 1.07 134 240 800 175 YES 2 100 NO 0 12 2.9 143 254 12.9 1.2 167 -1.4
